Pasithea Therapeutics (KTTA) Equity Average (2021 - 2026)

Pasithea Therapeutics' Equity Average history runs 6 years deep, the most recent figure standing at $55.0 million for Q1 2026.

• In Q1 2026, Equity Average rose 296.35% year-over-year to $55.0 million; the TTM figure through Mar 2026 stood at $55.0 million (up 296.35% YoY), while the FY2025 annual figure was $35.0 million, up 83.34% from the prior year.
• Equity Average came in at $55.0 million for Q1 2026 at Pasithea Therapeutics, up from $33.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $55.0 million in Q1 2026 to a low of $13.7 million in Q3 2025.
• A 5-year average of $31.4 million and a median of $32.0 million in 2023 frame the typical range for Equity Average.
• Across the five-year window, Equity Average jumped 8778.76% in 2022 and slumped 51.74% in 2024, its largest moves.
• Pasithea Therapeutics' Equity Average stood at $44.6 million in 2022, then slumped by 42.02% to $25.9 million in 2023, then sank by 37.04% to $16.3 million in 2024, then soared by 106.85% to $33.7 million in 2025, then jumped by 63.19% to $55.0 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $55.0 million, $33.7 million, and $13.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison